Today’s article highlights a biotech firm that, after being relatively quiet for several years, the market may begin to take notice of as it goes clinical with several of the therapies in its pipeline. More specifically, the company “is a preclinical-stage genome editing company focusing on developing novel therapeutics using the genome-editing process known as CRISPR/Cas9” – and Goldman Sachs rates the stock as a “Buy”. For more on this biotech, its pipeline of therapies, and the investment thesis for it, CLICK HERE.